Strategies for metabolite profiling based on liquid chromatography

Saurina, Javier; Sentellas, Sònia

doi:10.1016/j.jchromb.2017.01.011

Cited by 14 publications

(5 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The major identified metabolites are sometimes isolated or synthesized to investigate the efficacy and safety profile of a drug. Reactive metabolites which are generated from the metabolism may bind to the tissues or DNA, which can cause severe toxicities, leading to liver failure, which can in turn lead to its post‐marketing withdrawal (Saurina & Sentellas, 2017). Hence, a clear understanding of the structure of the metabolites as well as identification and early detection of reactive metabolites play a crucial role in the prediction of the potential toxicity of a molecule.…”

Section: Introductionmentioning

confidence: 99%

UHPLC–Q‐TOF–MS/MS‐based metabolite profiling of duvelisib and establishment of its metabolism mechanisms

Sonawane

Sahu

Jadav

et al. 2022

Biomedical Chromatography

View full text Add to dashboard Cite

Duvelisib is a dual inhibitor of phosphoinositide 3 kinase that received global approval by the US Food and Drug Administration in 2018 to treat follicular lymphoma after at least two prior systemic therapies. An extensive literature search revealed that, to date, metabolites of duvelisib have not been characterized and information on them is not available in any of the literature. Moreover, the metabolism pathway is yet to be established. This study aimed to investigate and characterize the metabolites of duvelisib generated in microsomes and S9 fractions. In this study, five duvelisib metabolites were identified using UHPLC-Q-TOF-MS/MS anal-

show abstract

Section: Introductionmentioning

confidence: 99%

UHPLC–Q‐TOF–MS/MS‐based metabolite profiling of duvelisib and establishment of its metabolism mechanisms

Sonawane

Sahu

Jadav

et al. 2022

Biomedical Chromatography

View full text Add to dashboard Cite

show abstract

“…In addition, in the bioanalysis area, the determination of drugs and related compounds in biological samples is essential not only for correlating drug exposure to efficacy but also for predicting adverse effects related to the drug or its metabolites. In bioanalysis, samples are analyzed for qualitative or quantitative purposes, i.e., for the identification and structural elucidation or the quantitation of exogenous or endogenous molecules [14][15][16]. Due to the inherent complexity of biological matrices, samples are usually subjected to clean-up or preconcentration procedures to enrich the sample and to eliminate possible interferences that can hinder the determination of the compound(s) of interest.…”

Section: Introductionmentioning

confidence: 99%

Ion Mobility–Mass Spectrometry for Bioanalysis

et al. 2021

Self Cite

View full text Add to dashboard Cite

This paper aims to cover the main strategies based on ion mobility spectrometry (IMS) for the analysis of biological samples. The determination of endogenous and exogenous compounds in such samples is important for the understanding of the health status of individuals. For this reason, the development of new approaches that can be complementary to the ones already established (mainly based on liquid chromatography coupled to mass spectrometry) is welcomed. In this regard, ion mobility spectrometry has appeared in the analytical scenario as a powerful technique for the separation and characterization of compounds based on their mobility. IMS has been used in several areas taking advantage of its orthogonality with other analytical separation techniques, such as liquid chromatography, gas chromatography, capillary electrophoresis, or supercritical fluid chromatography. Bioanalysis is not one of the areas where IMS has been more extensively applied. However, over the last years, the interest in using this approach for the analysis of biological samples has clearly increased. This paper introduces the reader to the principles controlling the separation in IMS and reviews recent applications using this technique in the field of bioanalysis.

show abstract

“…LC–MS is the most widely used method in the field of metabolomics because of its high sensitivity and ability to separate a wide range of molecules. Besides, LC–MS is suitable to analyze non‐volatile and non‐derivative metabolites (Saurina & Sentellas, 2017; Theodoridis et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

“…Six metabolic pathways are reported to play an important role in therapy‐related myelodysplasia syndrome, which involves at least four molecules (Cano et al, 2011). Saurina and Sentellas (2017) applied the LC–quadrupole time‐of‐flight–MS platform to monitor the levels of prostaglandins in the bone marrow mesenchymal stromal cells. Lysomonomethyl–phosphatidylethanolamines and other lipid metabolites have been identified as potential biomarkers of myeloid malignancies (de Oliveira et al, 2015).…”

Section: Introductionmentioning

confidence: 99%

Integrative metabolic profile of myelodysplastic syndrome based on UHPLC–MS

Yuan

Zhao

et al. 2021

Biomedical Chromatography

View full text Add to dashboard Cite

Myelodysplastic syndrome (MDS) is a neoplastic disease originating from hematopoietic stem cells. Currently, hematopoietic stem cell transplantation (HSCT) is the most effective cure, although lenalidomide, azacytidine, and decitabine have been applied to relieve symptoms of MDS. The purpose of this study was to evaluate the changes in endogenous metabolites by applying a UHPLC–MS (ultra–high‐performance liquid chromatography–MS) metabolomics approach and to investigate metabolic pathways related to MDS. An untargeted metabolomics approach based on UHPLC–MS in combination with multivariate data analysis, including partial least squares discrimination analysis and orthogonal partial least squares discriminant analysis, was established to investigate potential biomarkers in the plasma of MDS patients. As a result, 29 biomarkers were identified to distinguish between MDS patients, HSCT patients, and healthy controls, which were mainly related to inflammation regulation, amino acid metabolism, fatty acid metabolism, and energy metabolism. To our knowledge, this is the first time where plasma metabolomics was combined with HSCT to study the pathogenesis and therapeutic target of MDS. The identification of biomarkers and analysis of metabolic pathways could offer the possibility of discovering new therapeutic targets for MDS in the future.

show abstract

Strategies for metabolite profiling based on liquid chromatography

Cited by 14 publications

References 72 publications

UHPLC–Q‐TOF–MS/MS‐based metabolite profiling of duvelisib and establishment of its metabolism mechanisms

UHPLC–Q‐TOF–MS/MS‐based metabolite profiling of duvelisib and establishment of its metabolism mechanisms

Ion Mobility–Mass Spectrometry for Bioanalysis

Integrative metabolic profile of myelodysplastic syndrome based on UHPLC–MS

Contact Info

Product

Resources

About